In8Bio (INAB) Operating Expenses (2020 - 2026)

In8Bio has disclosed Operating Expenses across 7 years of filings, most recently posting $4.9 million for Q2 2026.

• In Q2 2026, Operating Expenses fell 5.11% year-over-year to $4.9 million; the TTM figure through Jun 2026 stood at $19.2 million (down 20.64% YoY), while the FY2025 annual figure was $19.9 million, down 35.24% from the prior year.
• Operating Expenses came in at $4.9 million for Q2 2026 at In8Bio, down from $5.3 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $8.7 million in Q2 2024 to a low of $4.0 million in Q3 2025.
• Average Operating Expenses over 5 years is $6.6 million, with a median of $7.1 million recorded in 2023.
• Year-over-year, Operating Expenses surged 160.05% in 2022 and plunged 44.2% in 2025.
• Over 5 years, Operating Expenses stood at $7.8 million in 2022, then decreased by 2.56% to $7.6 million in 2023, then fell by 18.08% to $6.2 million in 2024, then declined by 19.14% to $5.0 million in 2025, then declined by 1.95% to $4.9 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $4.9 million in Q2 2026, $5.3 million in Q1 2026, and $5.0 million in Q4 2025.